Updates are available Correction dated 2021-09-02
Click to view Correction: https://doi.org/10.1038/s41375-021-01396-x
-
Authors
Cervantes, Francisco http://orcid.org/0000-0003-2664-8131
Ross, David M.
Radinoff, Atanas
Palandri, Francesca http://orcid.org/0000-0001-8367-5668
Myasnikov, Alexandr
Vannucchi, Alessandro M.
Zachee, Pierre
Gisslinger, Heinz
Komatsu, Norio
Foltz, Lynda
Mannelli, Francesco
Passamonti, Francesco http://orcid.org/0000-0001-8068-5289
Gilotti, Geralyn
Sadek, Islam
Tiwari, Ranjan
Zor, Evren
Al-Ali, Haifa Kathrin http://orcid.org/0000-0001-5009-2239
- License Information
-
More Information
Article History
Received: 29 September 2020
Revised: 25 March 2021
Accepted: 26 April 2021
First Online: 20 May 2021
Change Date: 2 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01396-x
Compliance with ethical standards
:
: FC has served on speakers’ bureaus and advisory boards for Celgene and Novartis. DMR has received consultancy fees, honoraria, and research funding from Novartis, consultancy fees and honoraria from Bristol-Myers Squibb and Celgene, and research funding from Celgene. FPal has received speaker’s honoraria from Novartis. AMV has served on speakers’ bureaus for Gilead and Shire, and has served on the board of directors, speakers’ bureaus or advisory committees for and received research funding from Novartis. HG has received consultancy fees, honoraria, and research funding from, and served on speakers’ bureaus for AOP ORPHAN and Celgene, has received consultancy fees, honoraria, and research funding from Novartis, has received honoraria from and has served on speakers’ bureaus for Janssen Cilag. NK has received research funding from Fuso Pharmaceutical Industries and Wako Pure Chemical Industries, has received research funding from and has served on speakers’ bureaus for PharmaEssentia and Takeda, and has served on speakers’ bureaus for Novartis. LF has received consultancy fees from Pfizer, research funding from Constellation, Gilead, Incyte, and Promedior, and consultancy fees, honoraria, and research funding from Novartis. FPas has served on speakers’ bureaus for Novartis and Celgene/BMS. GG, IS, RT, and EZ are employees of Novartis. HKA-A has received consultancy fees, honoraria, and research funding from Novartis and Celgene, honoraria from Alexion, and consultancy fees and honoraria from Gilead. AR, AM, PZ, FM declare no conflicts of interest.
